ProShare Advisors’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

ProShare Advisors’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-6,605	Closed	-$70K	–	1666
2019 Q1	$70K	Buy	6,605 +1,424	+27%	+$14.2K	﹤0.01%	1599
2018 Q4	$41K	Sell	5,181 -1,042	-17%	-$15K	﹤0.01%	1531
2018 Q3	$120K	Buy	6,223 +561	+10%	+$10.2K	﹤0.01%	1664
2018 Q2	$102K	Sell	5,662 -1,086	-16%	-$16K	﹤0.01%	1706
2018 Q1	$72K	Sell	6,748 -1,108	-14%	-$17.8K	﹤0.01%	1657
2017 Q4	$331K	Buy	+7,856	New	+$352K	﹤0.01%	1332

Other funds holding SIOX

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

ProShare Advisors's SIOX Position: Q2 2019 in Review

ProShare Advisors sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q2 2019, closing a stake of 6,605 shares — an estimated $70K sold.

ProShare Advisors first reported a position in SIOX in Q4 2017 and held it in 6 quarters. The position peaked at $331K in Q4 2017. 39 funds tracked by Wall St. Rank hold SIOX as of Q2 2019.

ProShare Advisors reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
ProShare Advisors sold 6,605 Sio Gene Therapies Inc. Common Stock shares in Q2 2019, an estimated $70K.
ProShare Advisors first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2017 and held it in 6 quarters.
ProShare Advisors's Sio Gene Therapies Inc. Common Stock position peaked at $331K in Q4 2017.
39 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q2 2019.

Based on ProShare Advisors's 13F filing for Q2 2019, filed 13 Aug 2019.